



Entry into the European phase (EPO as designated or elected Office)

To the European Patent Office

European application number	EP20764639.9
PCT application number	PCT/EP2020/074134
PCT publication number	WO2021038078
Applicant's or representative's reference	T75093WOEP
International Filing Date	28.08.2020
International Searching Authority (ISA)	EP
International Preliminary Examining Authority (IPEA)	not applicable
1. Applicant Indications concerning the applicant(s) are contained in the international publication or were recorded by the International Bureau after the international publication. <input checked="" type="checkbox"/> Changes which have not yet been recorded by the International Bureau are set out here: <input type="checkbox"/>	
2. Representative Representative 1 Representative or association of representatives to be listed in the Register of European Patents and to whom communications are to be notified <div style="text-align: right;"> Name: Kilger, Dr. Ute Company: Boehmert & Boehmert Anwaltspartnerschaft mbB Address of place of business: Pettenkoferstraße 22 80336 Munich, Germany Telephone: +49 (89) 55 96 80 Fax: +49 (89) 55 96 85 090 E-mail: kilger@boehmert.de </div>	
3. Authorisation Representative 1 An individual authorisation is attached. <input type="checkbox"/> A general authorisation has been registered under No: <input type="checkbox"/> A general authorisation has been filed, but not yet registered. <input type="checkbox"/> The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase. <input type="checkbox"/>	
4. Request for examination Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid. <input checked="" type="checkbox"/> Request for examination in an admissible non-EPO language: <input type="checkbox"/> The/Each applicant hereby declares that he is an entity or a natural person under Rule 6(4) EPC. <input type="checkbox"/>	
5. Copies Additional copies of the documents cited in the supplementary European search report are requested. <input type="checkbox"/> Number of additional sets of copies	
6. Documents intended for proceedings before the EPO Number of claims on entry into the European phase: 25 6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents the application documents published by the International Bureau; where the publication includes a set of claims amended under Article 19 PCT, the latter <input checked="" type="checkbox"/>	

replaces the originally filed claims unless replaced by the amendments attached.	<input type="checkbox"/>
Comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are attached.	<input type="checkbox"/>
<i>Where necessary, further details should be attached as "Other documents"</i>	
6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents:	
the documents on which the international preliminary examination report is based, including any annexes	<input type="checkbox"/>
unless replaced by the amendments attached.	<input type="checkbox"/>
comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are enclosed.	<input type="checkbox"/>
<i>Where necessary, further details should be attached as "Other documents"</i>	
If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.	<input type="checkbox"/>
6.3 A copy of the results of the search carried out by the authority with which the previous application(s) whose priority is claimed was (were) filed is attached (R. 141(1) EPC).	<input type="checkbox"/>
7. Translations	
Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below:	<input type="checkbox"/>
<i>* In proceedings before the EPO as designated or elected Office (PCT I + II):</i>	
7.1 Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material	<input type="checkbox"/>
7.2 Translation of the priority application(s) (to be filed only at the EPO's request, Rule 53(3) EPC)	<input type="checkbox"/>
7.3 It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 53(3) EPC)	<input type="checkbox"/>
<i>* In addition, in proceedings before the EPO as designated Office (PCT I):</i>	
7.4 Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).	<input type="checkbox"/>
<i>* In addition, in proceedings before the EPO as elected Office (PCT II):</i>	
7.5 Translation of any annexes to the international preliminary examination report	<input type="checkbox"/>
8. Biological material	
The invention uses and/or relates to biological material deposited under Rule 31 EPC.	<input type="checkbox"/>
The particulars referred to in Rule 31(1)(c) EPC (if not yet known, the depositary institution and the identification reference(s)) [number, symbols, etc.] of the depositor are given in the international publication or in the translation submitted in Section 7 on:	<input type="checkbox"/>
page(s) / line(s)	
The receipt(s) of deposit issued by the depositary institution is (are) enclosed.	<input type="checkbox"/>
will be filed later.	<input type="checkbox"/>
Waiver of the right to an undertaking from the requester pursuant to Rule 33(2) EPC attached.	<input type="checkbox"/>
9. Nucleotide and amino acid sequences	
The international application discloses nucleotide and/or amino acid sequences.	<input checked="" type="checkbox"/>
9.1 The sequence listing was filed under Rule 5.2(a) PCT, or furnished to the EPO as ISA under Rule 13ter.1(a) PCT, or is otherwise available to the EPO, in computer-readable format in accordance with WIPO ST.25.	<input checked="" type="checkbox"/>
9.2	
The sequence listing is attached in computer-readable format in accordance with	<input type="checkbox"/>

- entry into EP phase		Total:		EUR	3 995.00
17. Annotations					
18. Signature(s) of applicant(s) or representative					
Place:	Munich				
Date:	28 March 2022				
Signed by:	/Dr. Ute Kilger/				
Representative name:	Ute Kilger				
Capacity:	(Representative)				

Table for section 6 of Form 1200.3

In accordance with the Notice from the European Patent Office dated 26 January 2009 concerning the 2009 fee structure (OJ EPO 2009, 118, and Guidelines for Examination in the EPO, April 2009, A-III, 13.2), the amount of the additional fee (Art. 2, item 1a, Rules relating to Fees) for the pages of this European patent application is calculated as follows:

Documents intended for proceedings before the EPO (R. 159 (1) (b) EPC) and for calculating the additional fee (Art. 2, item 1a, RFees):

	Page(s) from ... to ...	Number of pages
Description: International application as published	1 to 99	99
Claims: International application as published	100 to 104	5
Drawings: International application as published	1 to 15	15
Abstract: Default count: one page		1
Total number of pages		120
Fee-exempt pages (Art. 2, item 1a, RFees)		-35
Number of pages to be paid for		85
		(x 16 EUR per page)
Total amount payable	EUR	1360